CSI Market
Sign In | Register

Fortress Biotech Inc (FBIO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access FBIO Annual Cash Flow →
From Fortress Biotech Inc through Jun 30 2025, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income243.65
Depreciation & amortization0.19
Amortization of Other Assets5.60
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.02
Increase (Decrease) in Inventories-1.47
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment158.87
Share-based Compensation4.63
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Interest-
Noncash Interest Related Parties-
Contribution Of Services By Stockholder-
Change In Fair Value Of Common Stock Warrant Liability-
Change In Fair Value Of Embedded Conversion Feature-
Change In Preferred Stock Warrant Liability-
Change In Fair Value Of Short Term Investments-39.29
Change In Fair Value Of Subsidiary Convertible Note-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Noncash Or Part Noncash Acquisition Payables Assumed-
Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed-
Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed-
Amortization Of Forgivable Loans To Registered Representatives-
Amortization Of Deferred Clearing Credit-
Issuance Of Common Stock For Pik Interest Expense-
Unpaid Debt Offering Cost-
Issue Of Common Stock For Acquiring License Value-
Debt Conversion Original Debt Amount-
Liabilities Assumed-
Issuance Of Common Stock For License Expenses-
Allowance For Doubtful Accounts Receivable Recoveries-
Income taxes0.00
Trading Securities, Change in Unrealized Holding Gain (Loss)0.00
Accounts Receivable6.83
Increase (Decrease) in Accounts Payable and Accrued Liabilities2.31
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.01
Other Working Capital2.00
Other Noncash Expense0.00
Other net27.86
Payments for (Proceeds from) Other Operating Activities-304.91
Discontinued operations0.00
Net Cash flow from Operating Activities144.57
Investing Activities
Capital Expenditures-0.08
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payment Of Deposit For Facility Build Out-
Payment To Deposit For Leasehold Improvement-
Payment For Research And Development Licenses-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Proceeds from Other Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Proceeds from Divestiture of Interest in Consolidated Subsidiaries0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Proceeds from Collection of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.08
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.22
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Payments for Mortgage Deposits0.00
Other financing activities net0.00
Other net-28.52
Proceeds From Notes Payable Related Parties-
Payment For Notes Payable Related Party-
Proceeds From Notes Payable To Related Parties-
Payment Of Costs Related To Issuance Of Common Stock-
Issuance Of Convertible Preferred Stock Series B For Purchase Of Assets-
Payments Of Idb Notes Issuance Costs-
Transfer Of Restricted Cash-
Payment Of Notes Payable Asset Purchase Agreement-
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan-
Proceeds From Issuance Of At Market Offering-
Payment Of Nsc Note-
Payment Of Subordinated Short Term Debt Issuance Costs-
Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-27.30
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow144.50
Total Cash Flow117.20
4 historic quarters locked

Sign in to unlock the full Fortress Biotech Inc cash flow history.

Sign In Create Free Account

About Fortress Biotech Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-095964

Figures are derived from filed reports and may be restated. Historical data is subject to revision.